Related Experiment Videos
Statin use and ocular inflammatory disease risk
Jacob J Yunker1, Gerald McGwin, Russell W Read
1Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, 700 18th Street South, Suite 601, Birmingham, AL, 35233, USA. rwr@uab.edu.
Journal of Ophthalmic Inflammation and Infection
|March 22, 2013
Summary
Oral statin use may reduce the risk of developing ocular inflammatory disease (OID). The protective effect of statins against OID appears to increase with longer duration of use.
Area of Science:
- Ophthalmology
- Pharmacology
- Epidemiology
Background:
- Ocular inflammatory disease (OID) poses a significant clinical challenge.
- Understanding risk factors and protective agents for OID is crucial for patient management.
- Oral statins are widely prescribed medications with potential anti-inflammatory properties.
Purpose of the Study:
- To investigate the association between oral statin use and the subsequent risk of developing ocular inflammatory disease (OID).
- To quantify the potential protective effect of statins against OID incidence in a male veteran population.
Main Methods:
- Retrospective nested case-control study design.
- Inclusion of male patients with new OID diagnoses from the Birmingham Veterans Affairs Medical Center.
- Age-matched controls (10:1 ratio) without OID.
- Analysis of prescription data for statin use and comorbid conditions.
- Conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Main Results:
- Ninety-two incident cases of OID were identified.
- A trend towards reduced OID risk was observed in statin users (OR 0.50, 95% CI 0.20-1.23).
- A dose-dependent relationship was suggested, with longer statin use correlating with greater risk reduction.
Conclusions:
- Oral statin use may be associated with a decreased risk of developing ocular inflammatory disease.
- The potential protective effect of statins against OID is enhanced by longer duration of use.
- Further large-scale clinical studies are warranted to confirm the efficacy of statins in OID prevention.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...